Christian Schmidt 🇪🇺

Full-time investor - Micro caps. Co-Founder of a research and alert tool for investors.

[Christian Schmidt 🇪🇺 @finance_schmidt]

Performance

2026 YTD: 0,6%

Performance since 01.01.2017:

IRR: 31,94%
TTWROR: 656.24%

I will publish a detailed quarterly report with all buys and sells within two days via the link in my bio.

[Financial Skeptic @FinSkeptic]

I have just published a post on the newsletter website. I would like to point out that, as always, I am merely explaining the reasons behind my own investment decision. This is not investment advice, and everyone should always do their own research. $SEN.AX

[Christian Schmidt 🇪🇺 @finance_schmidt]

@RealWayneDaBang 3/3...likely scale the business much faster. Acquisition is the default exit model for medtech companies. It essentially functions as outsourced R&D for bigger players.

[Christian Schmidt 🇪🇺 @finance_schmidt]

1/* Explaining why $IRIX is interesting is relatively simple, but I still have to do a lot of heavy lifting to actually convince other investors.

For me, the thesis is straightforward. They have a genuine chance to emerge from this year as a profitable medtech company,...

[Christian Schmidt 🇪🇺 @finance_schmidt]

@RealWayneDaBang 2/3...companies out there, and they are usually unprofitable.

For a standalone medtech micro-cap, running a public company structure, an independent sales team, and distinct G&A functions is incredibly expensive.

An acquirer needs none of these overhead costs and would also...

[Christian Schmidt 🇪🇺 @finance_schmidt]

@RealWayneDaBang That aside, there are many more aspects of the strategy that are already visible: leveraging the Topcon and Novel connections, partnering with EyeProGo, and using MedScout. These are the levers they are pulling to drive growth.

[Christian Schmidt 🇪🇺 @finance_schmidt]

@RealWayneDaBang 3/3...work right now, as they already indirectly communicated their strategy. It all comes down to the new reimbursement environment, clinical data, and educating the physicians about it.

[Christian Schmidt 🇪🇺 @finance_schmidt]

@RealWayneDaBang That‘s step 2. First, they need to prove they can stay on a financially stable level. They are currently making a lot of bold moves that previous management teams avoided. Adding new sales staff now would only irritate the market, in my opinion.

[Christian Schmidt 🇪🇺 @finance_schmidt]

2/2...their positions, with BC being the exception here, though their selling was not that substantial. When they do buy, the stock price moves up sharply. For instance, a small purchase of approximately 50k AUD caused a 5% spike. It has truly become an illiquid stock.

[Christian Schmidt 🇪🇺 @finance_schmidt]

1/2 $IMB.AX I once made this comment as a joke, but it now genuinely appears that there are few shares left in the hands of retail investors. This scarcity explains the massive price swings we are seeing. Institutional investors are holding tight and only adding to...

[Christian Schmidt 🇪🇺 @finance_schmidt]

6/6...team that is actively moving past legacy constraints.

I recommend reading the latest earnings call transcript to get a better feel for management's initiatives.

https://t.co/idDJ9lR1ic

[Christian Schmidt 🇪🇺 @finance_schmidt]

5/*...management has multiple initiatives underway to expand margins, such as contract manufacturing.

The reason they can finally achieve what seemed impossible for decades is equally clear: a newly favorable reimbursement environment, strong clinical data, and a management...

[Christian Schmidt 🇪🇺 @finance_schmidt]

$IMB.AX The acquisition of Tyco NZ and Red Wolf has finally been completed.

[Christian Schmidt 🇪🇺 @finance_schmidt]

@ChristfriedW The wording has not worsened since at least Q3 2025.

[Christian Schmidt 🇪🇺 @finance_schmidt]

$NOW.V Headline results are as expected, offering neither a positive nor a negative surprise. However, they generated strong positive cash flow, even when adjusting for changes in working capital.